Samsung Biologics informs you about the notification of delaying public disclosure
Samsung Biologics informs you about the notification of delaying public disclosure
Samsung Biologics has received the notification about delaying public disclosure of Samsung Bioepis's financial audit reports from Korea Exchange(KRX) after closing session on March 13.
Accordingly, Samsung Biologics will submit the materials for explanation to the Korea Exchange(KRX) within 7 days.
Generally, accounting firms disclose financial audit reports ?for unlisted companies.
However, Samsung Biologics became aware of the fact that we had to disclose Samsung Bioepis's financial audit reports directly to the Korea Exchange(KRX) because Samsung Bioepis was classified as a major subsidiary of our company(more than 10% of total assets), even though Samsung Bioepis is an unlisted company.
This is caused by a simple mistake of the person in charge.
In the future, Samsung Biologics will further reinforce the training system and management process.
Samsung Biologics informs you about the notification of delaying public disclosure
Samsung Biologics has received the notification about delaying public disclosure of Samsung Bioepis's financial audit reports from Korea Exchange(KRX) after closing session on March 13.
Accordingly, Samsung Biologics will submit the materials for explanation to the Korea Exchange(KRX) within 7 days.
Generally, accounting firms disclose financial audit reports for unlisted companies.
However, Samsung Biologics became aware of the fact that we had to disclose Samsung Bioepis's financial audit reports directly to the Korea Exchange(KRX) because Samsung Bioepis was classified as a major subsidiary of our company(more than 10% of total assets), even though Samsung Bioepis is an unlisted company.
This is caused by a simple mistake of the person in charge.
In the future, Samsung Biologics will further reinforce the training system and management process.
Share article
Related Content